Clinical heterogeneity represents a great challenge for cancer therapeutics. Molecular classification of patients into different subtypes based on genetic or epigenetic characteristics has the potential to revolutionize the clinical care and mechanistic understanding of a wide spectrum of cancers, including endometrial carcinoma, the most common gynecological cancer affecting women.
Keywords: CTNNB1 mutation; cancer therapeutics; endometrial carcinoma; molecular subtyping; wnt signaling pathway.